MCID: MYS011
MIFTS: 31

Myasthenia Gravis Congenital

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Myasthenia Gravis Congenital

MalaCards integrated aliases for Myasthenia Gravis Congenital:

Name: Myasthenia Gravis Congenital 53
Myasthenia Gravis Pseudoparalytica 53
Erb-Goldflam Syndrome 53
Myasthenia Gravis 72
Congenital Mg 53

Classifications:



External Ids:

UMLS 72 C0026896

Summaries for Myasthenia Gravis Congenital

MalaCards based summary : Myasthenia Gravis Congenital, also known as myasthenia gravis pseudoparalytica, is related to thymoma and myasthenia gravis, and has symptoms including seizures, muscle weakness and tremor. An important gene associated with Myasthenia Gravis Congenital is RAPSN (Receptor Associated Protein Of The Synapse). The drugs Azathioprine and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and skeletal muscle.

Related Diseases for Myasthenia Gravis Congenital

Diseases in the Myasthenia Gravis family:

Myasthenia Gravis Congenital Juvenile Myasthenia Gravis
Adult-Onset Myasthenia Gravis

Diseases related to Myasthenia Gravis Congenital via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 19)
# Related Disease Score Top Affiliating Genes
1 thymoma 10.4
2 myasthenia gravis 10.4
3 congenital myasthenic syndrome 10.4
4 systemic lupus erythematosus 10.3
5 thymoma, familial 10.3
6 kearns-sayre syndrome 10.3
7 myotonia congenita 10.3
8 thymus cancer 10.3
9 myopathy 10.3
10 lupus erythematosus 10.3
11 muscular dystrophy 10.3
12 47,xyy 10.3
13 48,xyyy 10.3
14 myotonia 10.3
15 progressive muscular dystrophy 10.3
16 neonatal myasthenia gravis 10.1
17 lipomatosis, multiple 9.9
18 ptosis 9.9
19 pleomorphic lipoma 9.9

Comorbidity relations with Myasthenia Gravis Congenital via Phenotypic Disease Network (PDN):


Acute Cystitis Hypothyroidism
Respiratory Failure Swallowing Disorders

Graphical network of the top 20 diseases related to Myasthenia Gravis Congenital:



Diseases related to Myasthenia Gravis Congenital

Symptoms & Phenotypes for Myasthenia Gravis Congenital

UMLS symptoms related to Myasthenia Gravis Congenital:


seizures, muscle weakness, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness, facial paresis

Drugs & Therapeutics for Myasthenia Gravis Congenital

Drugs for Myasthenia Gravis Congenital (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Cimetropium Experimental, Investigational Phase 4 150521-16-7
4 Pharmaceutical Solutions Phase 4
5 Cola Phase 4
6 Tranquilizing Agents Phase 4
7 Anti-Anxiety Agents Phase 4
8 GABA Agents Phase 4
9 Adjuvants, Anesthesia Phase 4
10 Hypnotics and Sedatives Phase 4
11 Central Nervous System Depressants Phase 4
12 GABA Modulators Phase 4
13 Anesthetics, General Phase 4
14 Psychotropic Drugs Phase 4
15 Anesthetics, Intravenous Phase 4
16 Calamus Phase 4
17
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
18
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
19
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
21
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
22
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
23
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
24
Rocuronium Approved Phase 3 119302-91-9, 143558-00-3 441290
25
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
26
tannic acid Approved Phase 3 1401-55-4
27
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
28
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
29
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
30
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
31
Nifedipine Approved Phase 3 21829-25-4 4485
32
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
33
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
34
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
35 Immunoglobulin G Phase 3
36 Immunologic Factors Phase 2, Phase 3
37 Immunoglobulins, Intravenous Phase 3
38 gamma-Globulins Phase 3
39 Rho(D) Immune Globulin Phase 3
40 Calcineurin Inhibitors Phase 3
41 Vaccines Phase 3
42 Antirheumatic Agents Phase 2, Phase 3
43 Prednisolone acetate Phase 3
44 Methylprednisolone Acetate Phase 3
45 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
46 Antineoplastic Agents, Immunological Phase 2, Phase 3
47 Neuromuscular Nondepolarizing Agents Phase 3
48 Neuromuscular Blocking Agents Phase 3
49 Complement System Proteins Phase 3
50 Complement Inactivating Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial Unknown status NCT01842932 Phase 4 Phloroglucin;Cimetropium bromide;Placebo
2 A Randomized Trial of Plasma Exchange vs. IVIG in the Treatment of Myasthenia Gravis Completed NCT01179893 Phase 4
3 Comparison of Two Tapering Strategies of Prednisone in Patients With Generalised Myasthenia Gravis Treated With Prednisone and Azathioprine: a Single-blind Randomised Controlled Multicenter Study Completed NCT00987116 Phase 4 Prednisone - Azathioprine
4 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
5 Changes of Skin Resistance After Midazolam and After the End of Anaesthesia Completed NCT03791424 Phase 4 Midazolam
6 Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis Recruiting NCT03510546 Phase 4 Pyridostigmine;Placebo oral capsule
7 A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation Unknown status NCT02774239 Phase 3 Human normal immunoglobulin G (IgG)
8 A Randomized, Controlled Clinical Study of GB-0998 for Treatment of Generalized Myasthenia Gravis Completed NCT00515450 Phase 3
9 FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients Completed NCT00309088 Phase 3 tacrolimus;placebo
10 A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy Completed NCT01325571 Phase 3 Tacrolimus capsule;Placebo
11 FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients Completed NCT00309101 Phase 3 tacrolimus
12 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) Completed NCT01997229 Phase 3 Placebo
13 A Randomized, Double-Blind Study to Evaluate the Safety of Continued Treatment With CellCept in Patients With Well-Controlled Myasthenia Gravis Receiving a Stable Dose of Prednisone Completed NCT00408213 Phase 3 mycophenolate mofetil [CellCept];Placebo
14 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, 36-Week Trial to Assess the Efficacy and Safety of Adjunct Mycophenolate Mofetil (MMF) to Maintain or Improve Symptom Control With Reduced Corticosteroid in Subjects With Myasthenia Gravis Completed NCT00683969 Phase 3 mycophenolate mofetil (CellCept);placebo
15 ECU-MG-302, A Phase III, Open-label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG) Completed NCT02301624 Phase 3
16 IVIG Treatment Compared to Placebo in Patients With Myasthenia Gravis: A Randomized Clinical Trial Completed NCT00306033 Phase 3 Intravenous ImmuneGlobulin
17 A Trial of Mycophenolate Mofetil in Myasthenia Gravis Completed NCT00285350 Phase 3 mycophenolate mofetil
18 A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone Completed NCT00294658 Phase 3 prednisone alone
19 A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations Completed NCT02413580 Phase 3
20 Requirement of Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest - a Pilot Study Completed NCT01719770 Phase 3 rocuronium
21 Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis Completed NCT00261118 Phase 2, Phase 3 Rituximab
22 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Recruiting NCT03971422 Phase 3 Rozanolixizumab
23 An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Eculizumab in Pediatric Patients With Refractory Generalized Myasthenia Gravis Recruiting NCT03759366 Phase 3 Eculizumab
24 Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis Recruiting NCT03579966 Phase 3 Amifampridine Phosphate
25 A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness Recruiting NCT03770403 Phase 3
26 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness Recruiting NCT03669588 Phase 3
27 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis Recruiting NCT03920293 Phase 3 Placebo
28 Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis Recruiting NCT03914638 Phase 2, Phase 3 Salbutamol 4Mg Tablet;Placebo oral capsule
29 A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients Recruiting NCT03304054 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
30 The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Recruiting NCT01727193 Phase 3 Azathioprine;Leflunomide
31 A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG) Recruiting NCT02950155 Phase 3 Rituximab;Sodium Chloride solution
32 Postoperative Pain and Quality of Life for Patients Undergoing Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS:A Randomized Controlled Trial Recruiting NCT03521986 Phase 3
33 A 48-Week Prospective, Double-Blinded, Randomized, Cross-over Design in Multicenter Study of 250 Unit of Dysport Versus 50 Unit of Neuronox Injection For Cervical Dystonia in Thai Patients Not yet recruiting NCT03805152 Phase 3 Neuronox(R);Dysport (R)
34 Efficacy of Prednisone In the Treatment of Ocular Myasthenia: The EPITOME' Study Terminated NCT00995722 Phase 3 Prednisone;Placebo
35 Study of Different Doses of Nifedipine to Treat Preterm Labor Terminated NCT00137501 Phase 3 Nifedipine
36 A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis. Withdrawn NCT03165435 Phase 2, Phase 3
37 A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis Completed NCT02565576 Phase 2 Placebo;CFZ533
38 A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis Completed NCT03052751 Phase 2 UCB7665
39 Phase II Trial of Methotrexate in Myasthenia Gravis Completed NCT00814138 Phase 2 Methotrexate
40 A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Completed NCT02965573 Phase 2 Placebo
41 A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis Completed NCT02473952 Phase 2 IGIV-C;Placebo
42 B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis Completed NCT02110706 Phase 2 Rituximab;Placebo
43 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis Completed NCT02473965 Phase 2 IGIV-C;Placebo
44 Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis. Completed NCT00619671 Phase 1, Phase 2 Rituximab (Rituxan)
45 A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis Completed NCT02609022 Phase 1, Phase 2
46 A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects With Generalized Myasthenia Gravis (MG) Completed NCT01480596 Phase 2
47 FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
48 Augmentation of Parasympathetic Signaling With Pyridostigmine in Heart Failure Completed NCT01415921 Phase 2 Pyridostigmine Bromide
49 Effect of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure With Immunological Causes Completed NCT03174964 Phase 2 IVIg
50 Pilot Study of an ACh-E Inhibitor Upon Immune Activation Markers in HIV-1 Infected Patients Receiving Highly Active Antiretroviral Therapy (HAART) Showing an Incomplete Immune Response. Completed NCT00518154 Phase 2 Pyridostigmine tablets

Search NIH Clinical Center for Myasthenia Gravis Congenital

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Cyclophosphamide
Cyclosporine
Neostigmine
Neostigmine bromide
Neostigmine Methylsulfate
Pyridostigmine
Pyridostigmine Bromide

Genetic Tests for Myasthenia Gravis Congenital

Anatomical Context for Myasthenia Gravis Congenital

MalaCards organs/tissues related to Myasthenia Gravis Congenital:

41
Testes, Skin, Skeletal Muscle, B Cells, Thymus, Brain, Spinal Cord

Publications for Myasthenia Gravis Congenital

Articles related to Myasthenia Gravis Congenital:

(show top 50) (show all 68)
# Title Authors PMID Year
1
Associated morbidity of pediatric ptosis - a large, community based case-control study. 38
25115411 2014
2
Neonatal lupus erythematosus associated with unilateral pectoralis major atrophy. 38
21553209 2011
3
Founding years of clinical neurology in Berlin until 1933. 38
15370309 2004
4
[Receptor diseases in the field of neurology]. 38
10892286 2000
5
Arthrogryposis multiplex congenita. 38
9840670 1998
6
[The therapy of myasthenia gravis pseudoparalytica]. 38
1988277 1991
7
Congenital and acquired neuromuscular disease of young dogs and cats. 38
3300000 1987
8
[Computerized tomography of the mediastinum--results of a retrospective study]. 38
3630271 1987
9
[Significance of thymectomy in the treatment of myasthenia gravis pseudoparalytica in a patient sample in Bern]. 38
3775336 1986
10
[Infantile myasthenia gravis: report of a case diagnosed clinically]. 38
4091743 1985
11
[Thymectomy in myasthenia gravis pseudoparalytica]. 38
6524128 1984
12
[Case of systemic lupus erythematosus after thymectomy for myasthenia gravis pseudoparalytica]. 38
7163665 1982
13
Electrophysiology of neuromuscular junction disease: an appreciation of the contributions of Edward H. Lambert. 38
6302497 1982
14
[Myasthenia gravis pseudoparalytica as a result of penicillamine treatment of rheumatoid arthritis]. 38
7163666 1982
15
[Diagnosis and prognosis of myasthenia gravis (pseudoparalytica Erb-Goldflam]. 38
6104268 1980
16
[Electromyography of eye muscles in myasthenia gravis]. 38
7394081 1980
17
[Treatment of myasthenia gravis pseudoparalytica. Analysis of 60 personal cases and study of the literature]. 38
188592 1976
18
[Letter: Therapy of myasthenia gravis pseudoparalytica]. 38
1253742 1976
19
[Myasthenia gravis pseudoparalytica. The Erb-Goldflam syndrome]. 38
1255980 1976
20
[Results of x-ray therapy in patients with myasthenia gravis pseudoparalytica]. 38
4449752 1974
21
[Prognostic importance of thymic germinating centers in cases of myasthenia gravis pseudoparalytica]. 38
4449919 1974
22
[Contribution to pathohistology of the extrinsic ocular muscles in myasthenia gravis pseudoparalytica (author's transl)]. 38
4138873 1974
23
[Pathomorphous alterations in the central nervous system during myasthenia gravis pseudoparalytica with special regard to spinobulbar findings (author's transl)]. 38
4617456 1974
24
[Therapy of thymus neoplasms and of myasthenia gravis pseudoparalytica]. 38
4782941 1973
25
[Myasthenia gravis pseudoparalytica with special reference to concomitant neuromuscular and sponobulbar symptoms]. 38
4767121 1973
26
[Significance of thymectomy for the treatment of myasthenia gravis pseudoparalytica]. 38
4715781 1973
27
[Myasthenia gravis pseudoparalytica. Clinical picture, pathogenesis, therapy]. 38
4715780 1973
28
[Myocardial involvement in myasthenia gravis pseudoparalytica]. 38
4724517 1973
29
[Social medical aspects in myasthenia gravis pseudoparalytica]. 38
5558758 1971
30
[Thymectomy in the therapy of myasthenia gravis pseudoparalytica--anesthesia, preoperative and postoperative care]. 38
5087610 1971
31
[Results of thymectomy in myasthenia gravis pseudoparalytica]. 38
5555290 1971
32
[Therapy of myasthenia gravis pseudoparalytica]. 38
5523869 1970
33
[Manifestation of myasthenia gravis pseudoparalytica after thymomectomy]. 38
4102126 1970
34
[Myasthenia gravis pseudoparalytica and pregnancy]. 38
5392749 1969
35
[On the diagnosis and therapy of myasthenia gravis pseudoparalytica]. 38
5805931 1969
36
[The indication for thymectomy in myasthenia gravis pseudoparalytica]. 38
5240640 1967
37
[Myasthenia gravis pseudoparalytica in women in childbed]. 38
5589448 1967
38
[Further observations on side effects of intravenous administration of reverin in myasthenia gravis pseudoparalytica]. 38
6026478 1967
39
[Humoral antibodies against human musculoskeletal myosin fractions in myasthenia gravis pseudoparalytica]. 38
4955764 1965
40
[On myasthenia gravis pseudoparalytica]. 38
5322213 1965
41
[Problems of myasthenia gravis pseudoparalytica in pregnancy]. 38
13925859 1961
42
[Myasthenia gravis pseudoparalytica]. 38
13763410 1961
43
[A case of myasthenia in a 5 1/2-year-old boy (myasthenia gravis pseudoparalytica--Erb-Goldflam disease)]. 38
13774510 1960
44
[Diagnostic & therapeutic problems in myasthenia gravis pseudoparalytica]. 38
13630126 1959
45
[Treatment of myasthenia gravis pseudoparalytica; clinical testing and therapy with BC substances (BC40, BC47, BC48 and BC 51)]. 38
14430812 1959
46
[Surgical risk in myasthenia gravis pseudoparalytica patients (exclusive of the surgical treatment of the myasthenia itself)]. 38
13481528 1957
47
[Case of myasthenia in 3 year old girl (myasthenia gravis pseudoparalytica - ERB Goldlam disease)]. 38
13441332 1957
48
[Effect of polymethylene-bis-(N-methyl-carbamic acid-m-trimethylammonium-phenol) BC 40, BC 47, BC 48 on cholinesterase activity and muscle activity in myasthenia gravis pseudoparalytica]. 38
13409866 1957
49
[Problem of the pathogenesis of myasthenia gravis pseudoparalytica]. 38
13393039 1956
50
[Thymectomy in myasthenia gravis pseudoparalytica]. 38
13393400 1956

Variations for Myasthenia Gravis Congenital

Expression for Myasthenia Gravis Congenital

Search GEO for disease gene expression data for Myasthenia Gravis Congenital.

Pathways for Myasthenia Gravis Congenital

GO Terms for Myasthenia Gravis Congenital

Sources for Myasthenia Gravis Congenital

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....